Dr Reddy's to acquire Wockhardt divisions

18 Feb 2020

Deal sees 62 brands in multiple therapy areas and a manufacturing plant transfer to the company

Dr. Reddy’s Laboratories has agreed to buy select divisions of Wockhardt's branded generics business in India, Nepal, Sri Lanka, Bhutan and the Maldives for INR 18.5 billion (USD 258.5 million).

Dr Reddy's to acquire Wockhardt divisions

The business comprises a portfolio of 62 brands in multiple therapy areas such as respiratory, neurology, VMS, dermatology, gastroenterology, pain and vaccines, which would transfer to Dr Reddy’s along with related sales and marketing teams and a manufacturing plant located in Baddi, Himachal Pradesh with all plant employees.

The deal is expected to close in the first quarter of the financial year 2020-21.

“India is an important market for us and this acquisition will help in considerably scaling-up our domestic business," said G.V. Prasad, Co-Chairman and Managing Director of Dr Reddy’s. "The acquired portfolio shall enhance Dr Reddy’s presence in the high growth therapy areas with market-leading brands such as Practin, Zedex, Bro-zedex, Tryptomer and Biovac. We believe the portfolio holds a lot of potential and will get an impetus under Dr Reddy’s.”

Commenting on the transaction, Dr Habil Khorakiwala, Founder Chairman, Wockhardt Group, said: “The intended sale of Business portfolio is in line with the company’s strategic plan to shift from acute therapeutic areas to more chronic business such as anti-diabetes, CNS and to its niche antibiotic portfolio of NCEs. The divestment will also ensure adequate liquidity to bring in robust growth in the chronic domestic branded business, international operations, investments in biosimilars for the US market apart from the company’s global clinical trials of break-through anti-Infectives (NCEs approved under coveted QIDP1 program of US FDA) and R&D activities.“

Read More

Related news

FDA orders ranitidine withdrawal due to nitrosamine contamination risk

FDA orders ranitidine withdrawal due to nitrosamine contamination risk

2 Apr 2020

US drug regulator, the Food and Drug Administration has ordered the immediate withdrawal of all prescription and over-the-counter versions of heartburn drug, ranitidine – commonly known as Zantac – after concluding certain products may present an incre...

Read more 
UPDATED: COVID-19 PHARMA TRACKER

UPDATED: COVID-19 PHARMA TRACKER

2 Apr 2020

The latest coronavirus updates and developments impacting the global pharmaceutical supply chain…

Read more 
China focused on meeting international API demand amid pandemic, say officials

China focused on meeting international API demand amid pandemic, say officials

1 Apr 2020

China is stepping up its efforts to produce and ship active pharmaceutical ingredients (APIs), with a focus on meeting international demand, particularly for those showing potential to treat the COVID-19 disease, according to Chinese officials Tuesday.

Read more 
New blood test able to detect 50 cancer types

New blood test able to detect 50 cancer types

31 Mar 2020

Study data support blood test's ability to detect 50 types of cancer and identify where in the body the cancer is located.

Read more 
Cambrex names Troy Player as head of early stage development and testing

Cambrex names Troy Player as head of early stage development and testing

31 Mar 2020

Cambrex has appointed pharma industry veteran, Troy Player, as president, early stage development and testing, the contract development and manufacturing organisation said Tuesday.

Read more 
CDMO Ritedose chooses ChargePoint to ensure drug substance mixing process sterility

CDMO Ritedose chooses ChargePoint to ensure drug substance mixing process sterility

31 Mar 2020

The Ritedose Corporation, a contract development and manufacturing organisation (CDMO) with a focus on inhalation and ophthalmic products, has partnered with ChargePoint Technology to ensure the sterility of its drug substance mixing process.

Read more 
EMA to only issue electronic medicines certificates during COVID-19 pandemic

EMA to only issue electronic medicines certificates during COVID-19 pandemic

30 Mar 2020

The European Medicines Agency (EMA) said Monday it will only issue electronically signed and authenticated certificates for human and veterinary medicines in place of printed ones so it can continue to provide the documents during the COVID-19 pandemic...

Read more 
PandemiCam — our greatest chance yet to detect, monitor and beat COVID-19?

PandemiCam — our greatest chance yet to detect, monitor and beat COVID-19?

30 Mar 2020

Joint venture between Spinview and VR Media Technology creates device that provides accurate and fast detection of infectious people with far greater clarity than any single parameter test available today.

Read more 
New device offers a convenient way to monitor compressed air for viable particles

New device offers a convenient way to monitor compressed air for viable particles

30 Mar 2020

Specialist cleanroom microbiology solutions company offers the new SAS Super Pinocchio CR compressed air sampling device.

Read more 
CDMO Suven’s finished drug exports halted due to Indian COVID-19 lockdown

CDMO Suven’s finished drug exports halted due to Indian COVID-19 lockdown

25 Mar 2020

Indian contract development and manufacturing organisation, Suven Pharmaceuticals, has warned it cannot export finished products due to a shortage of raw materials following the country’s recent lockdown to fight the COVID-19 pandemic.

Read more